# Secondary Hyperparathyroidism-Chronic Kidney Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/secondary-hyperparathyroidism-chronic-kidney-disease

> 2 upcoming FDA catalysts in secondary Hyperparathyroidism-Chronic Kidney Disease: etelcalcetide (AMGN) on Jan to Apr 2029 (topline data readout); etelcalcetide (AMGN) on January 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 11, 2025 | [Doxercalciferol (gz427397) primary completion](https://sec-api.dev/pdufa/doxercalciferol-gz427397) | SNY | Secondary Hyperparathyroidism-Chronic Kidney Disease | withdrawn | "NCT02859896 (Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Sanofi; Results First Posted 2026-07-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02859896)) |
| Jan to Apr 2029 | [Etelcalcetide topline data readout](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism; Chronic Kidney Disease | scheduled | "NCT03633708 (A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03633708)) |
| January 2029 | [Etelcalcetide primary completion](https://sec-api.dev/pdufa/etelcalcetide) | AMGN | Secondary Hyperparathyroidism; Chronic Kidney Disease | scheduled | "NCT03633708 (A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03633708)) |

## Drugs

- [Doxercalciferol (gz427397)](https://sec-api.dev/pdufa/doxercalciferol-gz427397) (SNY)
- [Etelcalcetide](https://sec-api.dev/pdufa/etelcalcetide) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/secondary-hyperparathyroidism-chronic-kidney-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Secondary Hyperparathyroidism-Chronic Kidney Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/secondary-hyperparathyroidism-chronic-kidney-disease

```bibtex
@misc{secapidev_indications_secondary_hyperparathyroidism_chronic_kidney_disease_20261116,
  title        = {Secondary Hyperparathyroidism-Chronic Kidney Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/secondary-hyperparathyroidism-chronic-kidney-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_secondary_hyperparathyroidism_chronic_kidney_disease_20261116","title":"Secondary Hyperparathyroidism-Chronic Kidney Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/secondary-hyperparathyroidism-chronic-kidney-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
